Elisabetta Bugianesi

Summary

Country: Italy

Publications

  1. ncbi Insulin resistance: a metabolic pathway to chronic liver disease
    Elisabetta Bugianesi
    Gastroenterology Department, University of Turin, Turin, Italy
    Hepatology 42:987-1000. 2005
  2. doi Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes
    Anna Ludovica Fracanzani
    Department of Internal Medicine, Scientific Institute of Recovery and Cure Foundation IRCCS, Hospital Maggiore Policlinico, University of Milan, Milan, Italy
    Hepatology 48:792-8. 2008
  3. ncbi Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma
    Elisabetta Bugianesi
    Department of Gastroenterology, Ospedale S Giovanni Battista, University of Turin, Turin, Italy
    Gastroenterology 123:134-40. 2002
  4. ncbi A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease
    Elisabetta Bugianesi
    Department of Gastroenterology, University of Turin, Italy
    Am J Gastroenterol 100:1082-90. 2005
  5. doi Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C
    Ester Vanni
    Division of Gastro Hepatology, San Giovanni Battista Hospital, University of Turin, Turin, Italy
    Hepatology 50:697-706. 2009
  6. doi Type 2 diabetes mellitus and chronic hepatitis C: which is worse? Results of a long-term retrospective cohort study
    Chiara Giordanino
    Division of Gastroenterology, University of Turin, San Luigi Medical School, Orbassano, Italy
    Dig Liver Dis 44:406-12. 2012
  7. ncbi NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes
    Elisabetta Bugianesi
    Division of Gastro Hepatology, University of Turin, S Giovanni Battista Hospital, Corso Bramante 88, Turin 10126, Italy
    Curr Diab Rep 7:175-80. 2007
  8. doi Hepatic and cardiac steatosis: are they coupled?
    Elisabetta Bugianesi
    Division of Gastro Hepatology, Department of Internal Medicine, San Giovanni Battista Hospital, University of Turin, Corso Dogliotti 14, Turin, Italy
    Heart Fail Clin 8:663-70. 2012
  9. doi Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study
    Chiara Giordanino
    Gastroenterology, Molinette Hospital, Turin, Italy
    Am J Gastroenterol 103:2481-7. 2008
  10. ncbi Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis
    Elisabetta Bugianesi
    Gastroenterology Department, University of Turin, Italy
    Hepatology 44:1648-55. 2006

Collaborators

Detail Information

Publications25

  1. ncbi Insulin resistance: a metabolic pathway to chronic liver disease
    Elisabetta Bugianesi
    Gastroenterology Department, University of Turin, Turin, Italy
    Hepatology 42:987-1000. 2005
    ..Finally, the ability of insulin-sensitizing, pharmacological agents to treat NAFLD by reducing IR in the liver (metformin) and in the periphery (thiazolidinediones) are discussed...
  2. doi Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes
    Anna Ludovica Fracanzani
    Department of Internal Medicine, Scientific Institute of Recovery and Cure Foundation IRCCS, Hospital Maggiore Policlinico, University of Milan, Milan, Italy
    Hepatology 48:792-8. 2008
    ..07; 95% CI, 1.02-1.14), and diabetes (OR, 1.8; 95% CI, 1.4-2.3) in the overall series, serum ferritin and diabetes in those with increased ALT, and only HOMA-IR (OR, 1.97; 95% CI, 1.2-3.7) in patients with normal ALT...
  3. ncbi Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma
    Elisabetta Bugianesi
    Department of Gastroenterology, Ospedale S Giovanni Battista, University of Turin, Turin, Italy
    Gastroenterology 123:134-40. 2002
    ..Nonalcoholic steatohepatitis (NASH) may progress to cirrhosis; whether NASH plays also a role in the development of hepatocellular carcinoma (HCC) is unknown...
  4. ncbi A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease
    Elisabetta Bugianesi
    Department of Gastroenterology, University of Turin, Italy
    Am J Gastroenterol 100:1082-90. 2005
    ..We aimed to compare the usefulness of metformin versus prescriptive diet or vitamin E...
  5. doi Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C
    Ester Vanni
    Division of Gastro Hepatology, San Giovanni Battista Hospital, University of Turin, Turin, Italy
    Hepatology 50:697-706. 2009
    ..Substrate competition by increased lipid oxidation and possibly enhanced hepatic expression of inflammatory cytokines/mediators could be involved in the defective glucose regulation...
  6. doi Type 2 diabetes mellitus and chronic hepatitis C: which is worse? Results of a long-term retrospective cohort study
    Chiara Giordanino
    Division of Gastroenterology, University of Turin, San Luigi Medical School, Orbassano, Italy
    Dig Liver Dis 44:406-12. 2012
    ....
  7. ncbi NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes
    Elisabetta Bugianesi
    Division of Gastro Hepatology, University of Turin, S Giovanni Battista Hospital, Corso Bramante 88, Turin 10126, Italy
    Curr Diab Rep 7:175-80. 2007
    ..Although cardiovascular risk remains the major cause for excess mortality in type 2 diabetes mellitus, the risk of progressive liver disease should no longer be underscored...
  8. doi Hepatic and cardiac steatosis: are they coupled?
    Elisabetta Bugianesi
    Division of Gastro Hepatology, Department of Internal Medicine, San Giovanni Battista Hospital, University of Turin, Corso Dogliotti 14, Turin, Italy
    Heart Fail Clin 8:663-70. 2012
    ..Collectively these findings suggest the presence of complex and intertwined interrelationships between NAFLD, myocardial steatosis, and coronary artery disease...
  9. doi Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study
    Chiara Giordanino
    Gastroenterology, Molinette Hospital, Turin, Italy
    Am J Gastroenterol 103:2481-7. 2008
    ..Patients with chronic hepatitis C are at risk of developing type 2 diabetes mellitus (DM) and impaired fasting glucose (IFG), and this risk may increase among hepatitis C virus (HCV) patients not responding to an antiviral therapy...
  10. ncbi Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis
    Elisabetta Bugianesi
    Gastroenterology Department, University of Turin, Italy
    Hepatology 44:1648-55. 2006
    ..Virus-induced hepatic steatosis as seen in CHC-3 does not contribute significantly to liver fibrosis...
  11. pmc Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C
    Gianluca Svegliati-Baroni
    Department of Gastroenterology, Polytechnic University of Marche, Ancona, Italy
    Gut 60:108-15. 2011
    ..To study the mechanism(s) linking insulin resistance (IR) to hepatic fibrosis and the role of the epithelial component in tissue repair and fibrosis in chronic hepatitis C (CHC)...
  12. doi The interaction of metabolic factors with HCV infection: does it matter?
    Elisabetta Bugianesi
    Department of Internal Medicine, University of Turin, Italy
    J Hepatol 56:S56-65. 2012
    ..Thus, targeted lifestyle and pharmacological measures are urgently warranted in chronic hepatitis C with metabolic alterations...
  13. ncbi Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity
    Elisabetta Bugianesi
    Division of Gastroenterology, University of Turin, Ospedale San Giovanni Battista, Corso Bramante 88, I 10126 Torino, Italy
    J Clin Endocrinol Metab 90:3498-504. 2005
    ..Hypoadiponectinemia in NAFLD is part of a metabolic disturbance characterized by ectopic fat accumulation in the central compartment...
  14. doi From the metabolic syndrome to NAFLD or vice versa?
    Ester Vanni
    Division of Gastro Hepatology, San Giovanni Battista Hospital, University of Turin, c so Bramante 88, 10126 Turin, Italy
    Dig Liver Dis 42:320-30. 2010
    ..Recently nuclear receptors have emerged as key regulators of lipid and carbohydrate metabolism for which specific pharmacological ligands are available, making them attractive therapeutic targets for NAFLD and NASH...
  15. ncbi Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver
    Elisabetta Bugianesi
    Division of Gastro Hepatology, Department of Internal Medicine, University of Turin, Turin, Italy
    Hepatology 39:179-87. 2004
    ..Increased ferritin levels are markers of severe histologic damage, but not of iron overload. Iron burden and HFE mutations do not contribute significantly to hepatic fibrosis in the majority of patients with NAFLD...
  16. ncbi Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment
    Elisabetta Bugianesi
    Department of Gastroenterology, San Giovanni Battista Hospital, University of Turin, Corso Bramante 88, I 10127 Turin, Italy
    Best Pract Res Clin Gastroenterol 18:1105-16. 2004
    ..Large, long-term, placebo-controlled randomized studies are eagerly awaited. Outside controlled studies, nutritional counselling and physical exercise aimed at moderate weight loss remain the basis of any therapeutic intervention...
  17. ncbi Is liver disease a threat to patients with metabolic disorders?
    Giulio Marchesini
    Unit of Metabolic Diseases, Alma Mater Studiorum University, Bologna, and San Giovanni Battista Hospital, Turin, Italy
    Ann Med 37:333-46. 2005
    ....
  18. pmc The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease
    Luca Miele
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
    Gastroenterology 135:282-291.e1. 2008
    ..Based on its role in liver growth and repair, we explored whether Kruppel-like factor 6 (KLF6) plays a role in NAFLD progression...
  19. ncbi Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome
    Giulio Marchesini
    Unit of Metabolic Diseases and Department of Internal Medicine, Alma Mater Studiorum University of Bologna, Bologna, Italy
    Hepatology 37:917-23. 2003
    ..The increasing prevalence of obesity, coupled with diabetes, dyslipidemia, hypertension, and ultimately the metabolic syndrome puts a very large population at risk of forthcoming liver failure in the next decades...
  20. ncbi Non-alcoholic steatohepatitis in patients cared in metabolic units
    Giulio Marchesini
    Unit of Metabolic Diseases, Department of Internal Medicine and Gastroenterology, University of Bologna, Alma Mater Studiorum, Via Massarenti 9, Policlinico S Orsola, I 40138 Bologna, Italy
    Diabetes Res Clin Pract 63:143-51. 2004
    ..Liver biopsy is recommended for diagnostic and prognostic purposes, as well as for testing treatment effects in controlled trials...
  21. ncbi Nonalcoholic fatty liver disease (NAFLD) and cardiac lipotoxicity: Another piece of the puzzle
    Elisabetta Bugianesi
    Hepatology 47:2-4. 2008
  22. ncbi Intrauterine growth retardation, insulin resistance, and nonalcoholic fatty liver disease in children
    Valerio Nobili
    Liver Unit, Research Institute, Bambino Gesu Children s Hospital, Piazza S Onofrio 4, 00165 Rome, Italy
    Diabetes Care 30:2638-40. 2007
  23. ncbi Nonalcoholic fatty liver disease and the metabolic syndrome
    Giulio Marchesini
    Unit of Metabolic Diseases, Alma Mater Studiorum University of Bologna, Italy
    Curr Opin Lipidol 16:421-7. 2005
    ..Insulin resistance is the common factor connecting obesity, diabetes, hypertension and dyslipidemia with fatty liver and the progression of hepatic disease to steatohepatitis, fibrosis, cirrhosis and hepatocellular carcinoma...
  24. ncbi Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease
    Nicola Villanova
    Unit of Metabolic Diseases, Alma Mater Studiorum University of Bologna, Policlinico S Orsola Malpighi, Via Massarenti 9, I 40138 Bologna, Italy
    Hepatology 42:473-80. 2005
    ..The risk of advanced liver disease is well recognized in NAFLD patients, but the large majority of cases might experience cardiovascular disease in the long term, indirectly limiting the burden of liver failure...
  25. ncbi Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study
    Luca Valenti
    Department of Internal Medicine, Universita di Milano, Ospedale Policlinico Mangiagalli Regina Elena IRCCS, Milano, Italy
    Am J Gastroenterol 102:1251-8. 2007
    ..Aims of this study were to define the relationship between ferritin and iron stores in patients with NAFLD, the effect of iron depletion on insulin resistance, and whether basal ferritin levels influence treatment outcome...